Dataset Information

Fighting Post-COVID and ME/CFS - development of curative therapies.

ABSTRACT: The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.

SUBMITTER: Scheibenbogen C

PROVIDER: S-EPMC10309204 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Fighting Post-COVID and ME/CFS - development of curative therapies.

Scheibenbogen Carmen C Bellmann-Strobl Judith Theresia JT Heindrich Cornelia C Wittke Kirsten K Stein Elisa E Franke Christiana C Prüss Harald H Preßler Hannah H Machule Marie-Luise ML Audebert Heinrich H Finke Carsten C Zimmermann Hanna Gwendolyn HG Sawitzki Birgit B Meisel Christian C Toelle Markus M Krueger Anne A Aschenbrenner Anna C AC Schultze Joachim L JL Beyer Marc D MD Ralser Markus M Mülleder Michael M Sander Leif Erik LE Konietschke Frank F Paul Friedemann F Stojanov Silvia S Bruckert Lisa L Hedderich Dennis M DM Knolle Franziska F Riemekasten Gabriela G Vehreschild Maria J G T MJGT Cornely Oliver A OA Behrends Uta U Burock Susen S

Frontiers in medicine 20230615

The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with pos ...[more]

PMID: 37396922

Similar Datasets

Project description:BackgroundMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severely debilitating condition which markedly restricts activity and function of affected people. Since the beginning of the COVID-19 pandemic ME/CFS related to post-acute COVID-19 syndrome (PACS) can be diagnosed in a subset of patients presenting with persistent fatigue 6 months after a mostly mild SARS-CoV-2 infection by fulfillment of the Canadian Consensus Criteria (CCC 2003). Induction of autoimmunity after viral infection is a mechanism under intensive investigation. In patients with ME/CFS, autoantibodies against thyreoperoxidase (TPO), beta-adrenergic receptors (ß2AR), and muscarinic acetylcholine receptors (MAR) are frequently found, and there is evidence for effectiveness of immunomodulation with B cell depleting therapy, cyclophosphamide, or intravenous immunoglobulins (IVIG). Preliminary studies on the treatment of ME/CFS patients with immunoadsorption (IA), an apheresis that removes antibodies from plasma, suggest clinical improvement. However, evidence from placebo-controlled trials is currently missing.MethodsIn this double-blinded, randomized, sham-controlled, exploratory trial the therapeutic effect of five cycles of IA every other day in patients with ME/CFS, including patients with post-acute COVID-19 chronic fatigue syndrome (PACS-CFS), will be evaluated using the validated Chalder Fatigue Scale, a patient-reported outcome measurement. A total of 66 patients will be randomized at a 2:1 ratio: 44 patients will receive IA (active treatment group) and 22 patients will receive a sham apheresis (control group). Moreover, safety, tolerability, and the effect of IA on patient-reported outcome parameters, biomarker-related objectives, cognitive outcome measurements, and physical parameters will be assessed. Patients will be hospitalized at the clinical site from day 1 to day 10 to receive five IA treatments and medical visits. Four follow-up visits (including two visits at site and two visits via telephone call) at month 1 (day 30), 2 (day 60), 4 (day 120), and 6 (day 180; EOS, end of study visit) will take place.DiscussionAlthough ME/CFS including PACS-CFS causes an immense individual, social, and economic burden, we lack efficient therapeutic options. The present study aims to investigate the efficacy of immunoadsorption and to contribute to the etiological understanding and establishment of diagnostic tools for ME/CFS.Trial registrationRegistration Number: NCT05710770 . Registered on 02 February 2023.

Dataset Information

Fighting Post-COVID and ME/CFS - development of curative therapies.

Publications

Fighting Post-COVID and ME/CFS - development of curative therapies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets